Advances in pancreatic cancer early diagnosis, prevention, and treatment: The past, the present, and the future
2025/09/19 by Alessandro Mannucci, Ajay Goel · 25 citations
Medicine · Biochemistry, Genetics and Molecular Biology · #Pancreatic and Hepatic Oncology Research #Pancreatitis Pathology and Treatment #Cancer Genomics and Diagnostics
paper · doi:10.3322/caac.70035
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with a dismal prognosis, largely because of late-stage diagnosis and therapeutic resistance. PDAC incidence has been rising, with modifiable and non-modifiable risk factors contributing to disease development. Chronic pancreatitis, diabetes mellitus, smoking, obesity, and familial predisposition have been implicated in PDAC pathogenesis. Early clinical manifestations are vague and insidious; therefore, PDAC is often diagnosed at an advanced stage, limiting curative treatment options. Efforts to improve early detection have focused on serum biomarkers (e.g., carbohydrate antigen 19-9), imaging modalities, and liquid biopsies. Endoscopic ultrasound and magnetic resonance imaging have demonstrated potential in identifying early-stage disease in certain high-risk populations. Surgical resection remains the only potentially curative option, but only 15%-20% of patients have resectable disease at diagnosis. Neoadjuvant chemotherapy has emerged as a promising strategy to improve resectability and survival outcomes. For patients with locally advanced or metastatic PDAC, combination chemotherapy regimens such as FOLFIRINOX (folinic acid, 5-fluorouracil, irinotecan, and oxaliplatin), NALIRIFOX (5-fluorouracil, oxaliplatin, liposomal irinotecan, and leucovorin), and combined gemcitabine/nanoparticle albumen-bound paclitaxel offer survival benefits, although toxicity remains a concern, especially for platinum-based therapies. Several breakthroughs in molecular profiling have led to the development of targeted therapies, including sotorasib and olaparib. Immunotherapy has shown limited success in PDAC due to its immunosuppressive tumor microenvironment. However, novel combination approaches are under investigation, including quadruplet therapy, immune checkpoint inhibitors with oncolytic viruses, stromal-targeting agents, and personalized neoantigen vaccines. Key priorities for future research include identifying reliable biomarkers for early detection, refining patient selection for targeted therapies, and developing innovative strategies to overcome treatment resistance.
Citations
Cited by
- F41, a Novel Fungal Indole-Diterpenoid, Overcomes Gemcitabine Resistance in Pancreatic Cancer by Inducing ER Stress. [europepmc]
- Research progress on early diagnostic markers for pancreatic cancer. [europepmc]
- Discovery of a Secretory Granule Lumen-Enriched Serum Protein Signature in Resectable Pancreatic Ductal Adenocarcinoma. [europepmc]
- Optimized production and characterization of ulvan from Ulva Lactuca with in vitro biological activities. [europepmc]
- NDUFS1-Mediated Mitochondrial Complex I Activity Maintains Pancreatic Cancer Stemness by Promoting PAX2 Hypomethylation. [europepmc]
- Targeting IL-12 for pancreatic cancer immunotherapy: advances in delivery strategies and clinical translation. [europepmc]
- Malpractice claims for pancreatic cancer in Norway: claim-rates, injury domains, claim outcomes and indemnity compensation. [europepmc]
- High Intratumoral PROS1 Expression Correlates with Improved Survival and Is Associated with Suppressed Oncogenic Signaling in Pancreatic Ductal Adenocarcinoma. [europepmc]
- Integrative systems biology and drug repurposing reveal key regulatory hubs and a prognostic signature in gastric cancer. [europepmc]
- From Pyroptosis Heterogeneity to an Interpretable Prognostic Signature for Risk Stratification and Therapy Insights in Pancreatic Adenocarcinoma. [europepmc]
- Microbiome and Diet Interplay: An Emerging Frontier in PDAC Diagnosis and Prevention. [europepmc]
- Multiomics Analysis of Nucleotide Metabolism Highlights the Important Role of Adenylate Kinase 4 in Pancreatic Cancer. [europepmc]
- Distinct Inflammatory and Dissemination Signatures Defined by Macrophage Migration Inhibitory Factor (MIF), Interleukin-8 (IL-8/CXCL8), and Stem Cell Factor (SCF) in Pancreatic Adenocarcinoma. [europepmc]
- A Biomarker Panel for the Detection of Pancreatic Cancer. [europepmc]
- Pancreatic Cancer in the Holobiont and Therapeutic Targets: A Review. [europepmc]
- Development and validation of a machine learning model for predicting liver metastasis in pancreatic cancer: a retrospective cohort study. [europepmc]
- Impact of preoperative body weight on short-term and long-term prognosis after pancreatic resection for pancreatic ductal adenocarcinoma: a multicenter study. [europepmc]
- Recent Advances in Pancreatic Cancer and Biliary Tract Cancers: Biology, Biomarkers, and Evolving Systemic Therapy. [europepmc]
- Methylation-regulated miR-374a-5p and miR-374b-5p suppress glycolysis and malignant progression of head and neck squamous cell carcinoma by targeting DEPDC1. [europepmc]
- Efficacy and safety of National Centralized Drug Procurement-procured versus non-National Centralized Drug Procurement oxaliplatin in unresectable or metastatic pancreatic cancer: a retrospective cohort study. [europepmc]
- CT-based vascular invasion in pancreatic ductal adenocarcinoma compared with intraoperative and histological findings. [europepmc]
- Distal and Total Pancreatectomy With En Bloc Celiac Axis Resection for Pancreatic Cancer at a High-Volume Center. [europepmc]
- Dynamics of Circulating Tumor DNA (ctDNA) Predict Treatment Efficacy and Prognosis in Patients With Advanced Pancreatic Cancer: A Prospective Large-Cohort Study. [europepmc]
- Focused Ultrasound in Pancreatic Ductal Adenocarcinoma: Mechanisms, Preclinical Evidence, and Emerging Clinical Applications [europepmc]
- A Vascular Invasion-Related Gene Signature Identifies NUP35 as a Driver of Angiogenesis and Poor Prognosis in Pancreatic Ductal Adenocarcinoma [europepmc]
Related